Search results for "clinical studie"

showing 10 items of 34 documents

‘Not at all what I had expected’: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study

2021

Background: Extended-release naltrexone (XR-NTX), an opioid antagonist, has demonstrated equal treatment outcomes, in terms of safety, opioid use, and retention, to the recommended OMT medication buprenorphine. However, premature discontinuation of XR-NTX treatment is still common and poorly understood. Research on patient experiences of XR-NTX treatment is limited. We sought to explore participants' experiences with discontinuation of treatment with XR-NTX, particularly motivation for XR-NTX, experiences of initiation and treatment, and rationale for leaving treatment. Methods: We conducted qualitative, semi-structured interviews with participants from a clinical trial of XR-NTX. The study…

Malemedicine.medical_specialtymedicine.drug_classNarcotic Antagonistsmedia_common.quotation_subjectMedicine (miscellaneous)Injections IntramuscularNaltrexonemedicineHumansVDP::Medisinske Fag: 700PsychiatryQualitative Researchmedia_commonbusiness.industryClinical Studies as TopicAbstinenceOpioid-Related DisordersNaltrexoneBuprenorphineDiscontinuationAnalgesics OpioidClinical trialPsychiatry and Mental healthClinical PsychologyVDP::Medisinske Fag: 700::Helsefag: 800Delayed-Action PreparationsFemalePshychiatric Mental HealthThematic analysisbusinesshuman activitiesOpioid antagonistQualitative researchmedicine.drugBuprenorphine
researchProduct

Very high specific activity erbium 169Er production for potential receptor-targeted radiotherapy

2019

Erbium 169Er is one of the most interesting radiolanthanides for new potential receptor-targeted β− therapy applications due to its low energy β− emissions, very low intensity ɣ rays and the possibility to use 68Ga or 44Sc as companion for diagnostic in a theranostics approach. Currently it can be produced in reactors through the neutron activation of highly enriched 168Er. The low specific activity of the produced carrier-added 169Er is limiting its use for receptor-targeted therapy. Nonetheless it is used for radiosynoviorthesis of small joints. The aim of this work is to develop a new large-scale production method for the supply of very high specific activity 169Er. Highly enriched 168Er…

Nuclear and High Energy PhysicsHIGH SPECIFIC ACTIVITIESMaterials scienceTargeted Radiotherapychemistry.chemical_elementLASER IONIZATION7. Clean energy030218 nuclear medicine & medical imaginglaw.inventionErbium03 medical and health sciences0302 clinical medicinePRECLINICAL STUDIESlaw[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Production (economics)HIGH SPECIFIC ACTIVITYIrradiationInstrumentationComputingMilieux_MISCELLANEOUSATOM LASERSRadiochemistrySELECTIVE IONIZATIONNuclear reactorERBIUMRESONANT LASER IONIZATIONLARGE SCALE PRODUCTIONSchemistryHigh specific activityER-169030220 oncology & carcinogenesisSEPARATION EFFICIENCYTARGETED RADIOTHERAPYIONIZATIONSpecific activityRECEPTOR-TARGETED THERAPYNeutron activationNUCLEAR REACTORSNuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms
researchProduct

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised pros…

2008

Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30% and median overall survival of 9-11 months in selected patients. Yet these combinations have not been subject to a randomised trial to overcome selection bias, a major problem in CUP. We randomised 92 patients to either paclitaxel/carboplatin (arm A) or the non-platinum non-taxane regimen gemcitabine/vinorelbine (arm B). The primary endpoint was rate of practicability as defined: application of >or=2 cycles of therapy (1) with a maximal delay of 1 week (2) and survival of >or=8 months (3). Practicability was shown in 52.4% (95% CI 36-68%) in arm A and in 42.2% (95…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentneoplasmsVinorelbineVinblastineDeoxycytidineCarboplatinchemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineClinical endpointHumansProspective StudiesAgedProportional Hazards ModelsChemotherapyTaxaneclinical trial phase IIbusiness.industryVinorelbineMiddle AgedGemcitabinemedical oncologyGemcitabineCarboplatinSurgeryErbB ReceptorsRegimenOncologyDocetaxelchemistryrandomized controlled trialunknown primaryNeoplasms Unknown Primaryanti-neoplastic-combined chemotherapy protocolsFemalebusinessmedicine.drugBritish journal of cancer
researchProduct

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

2006

Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseaseendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentpancreatic cancerAntineoplastic AgentschemotherapyAntimetaboliteDeoxycytidinechemistry.chemical_compoundHemoglobinsLeukocyte CountInternal medicinePancreatic cancerClinical StudiesmedicineHumansIn patientAgedNeoplasm StagingChemotherapyDose-Response Relationship Drugbusiness.industryPlatelet CountgemcitabineMiddle Agedmedicine.diseaseepirubicinGemcitabineSurgeryPancreatic NeoplasmsOncologychemistryDeoxycytidineFemalebusinessEpirubicinmedicine.drugBritish Journal of Cancer
researchProduct

Myoglobin, expressed in brown adipose tissue of mice, regulates the content and activity of mitochondria and lipid droplets

2021

Abstract The identification of novel physiological regulators that stimulate energy expenditure through brown adipose tissue (BAT) activity in substrate catalysis is of utmost importance to understand and treat metabolic diseases. Myoglobin (MB), known to store or transport oxygen in heart and skeletal muscles, has recently been found to bind fatty acids with physiological constants in its oxygenated form (i.e., MBO2). Here, we investigated the in vivo effect of MB expression on BAT activity. In particular, we studied mitochondrial function and lipid metabolism as essential determinants of energy expenditure in this tissue. We show in a MB-null (MBko) mouse model that MB expression in BAT i…

PalmitatesOxidative phosphorylationMitochondrion1307 Cell BiologyMiceAdipose Tissue BrownLipid dropletBrown adipose tissueRespiration1312 Molecular BiologymedicineAnimalsHumansPPAR alpha11434 Center for Clinical StudiesMuscle SkeletalMolecular BiologyUncoupling Protein 1Mice KnockoutMyoglobinChemistryProteinsThermogenesisLipid metabolismLipid DropletsCell BiologyMetabolism10081 Institute of Veterinary PhysiologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaCell biologyOxygenDisease Models AnimalAdipocytes Brownmedicine.anatomical_structure10076 Center for Integrative Human Physiology570 Life sciences; biologyApoptosis Regulatory ProteinsEnergy MetabolismThermogenesisBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
researchProduct

Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B-restoration by exogenous interleuki…

2002

SUMMARYInsufficient stimulatory capacities of autologous dendritic cells (DC) may contribute in part to impaired T cell stimulation and therefore viral persistence in patients with chronic hepatitis B virus (HBV) infection. In order to characterize the antigen presenting functions of DC from chronic HBV carriers and controls antigen specific T cell responses were analysed. CD34+ peripheral blood progenitor cells were differentiated to immature DC in the presence of GM-CSF, IL-6/IL-6R fusion protein and stem cell factor. Proliferative CD4+ T cell responses and specific cytokine release were analysed in co-cultures of DC pulsed with HBV surface and core antigens or tetanus toxoid and autologo…

Recombinant Fusion ProteinsT cellImmunologyAntigen presentationBiologyHepatitis B ChronicImmune systemAntigenClinical StudiesTetanus ToxoidmedicineHumansImmunology and AllergyCells CulturedAntigen PresentationLymphokinesStem Cell FactorHepatitis B Surface AntigensInterleukin-6Granulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationConvalescenceDendritic CellsT-Lymphocytes Helper-InducerT helper cellDendritic cellHepatitis Bmedicine.diseaseHepatitis B Core AntigensInterleukin-12VirologyCoculture Techniquesmedicine.anatomical_structureImmunologyInterleukin 12
researchProduct

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper

2015

While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. Rules of rational decision making in conditions of uncertainty should be rigorously followed and would need widely informative clinical trials. In principle, any piece of new evidence would need to be exploited in rare cancers. Methodologies to explicitly weigh and combine all the available evidence should be refined, and the Bayesian logic can be instrumental to this end. Likewise, Bayesian-design trials may help optimize the low number of patients liable to be enrolled in …

Research designPathologyData baseResearch methodologyElectronic medical recordDiseaseReviewProceduresTreatment responseClinical trials; Rare cancers; Research methodology; Clinical Studies as Topic; Humans; Neoplasms; Rare Diseases; Research Design; Hematology; OncologyClinical trialsNeoplasmsReimbursementPriority journaleducation.field_of_studyClinical Studies as TopicClinical studies as topicHematologyRare diseasesEuropeOncologyResearch designResearch DesignClinical decision makingHumanmedicine.medical_specialtyPractice guidelineCase findingPopulationHealth care qualityReviewsCancer researchClinical studyRare DiseasesSDG 3 - Good Health and Well-beingConceptual frameworkmedicineHumansRare cancersTumor markerIntensive care medicineeducationAntineoplastic activityFlexibility (engineering)Surrogate endpointbusiness.industryMethodologyRare cancerStudy designCancer survivalReimbursementClinical trialClinical trials; Rare cancers; Research methodology; Hematology; OncologyPatient informationClinical effectivenessPosition paperNeoplasmbusinessRare disease
researchProduct

The Role of Nutraceuticals in Statin Intolerant Patients.

2018

Abstract Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activ…

Statinmedicine.drug_classDiseasecardiovascular risk ; dyslipidemia ; nutraceuticals ; position paper ; statin intolerance030204 cardiovascular system & hematologyBioinformaticsKlinikai orvostudományok03 medical and health sciences0302 clinical medicineNutraceuticalEzetimibeStatin intoleranceRed yeast riceMedicineHumansPosition paper030212 general & internal medicineEndothelial dysfunctionDyslipidemiasbusiness.industryClinical Studies as TopicOrvostudományokmedicine.diseaseCardiovascular risk3. Good healthDyslipidemiaDietary SupplementsArterial stiffnesslipids (amino acids peptides and proteins)nutraceuticalHydroxymethylglutaryl-CoA Reductase InhibitorNutraceuticalsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaposition papermedicine.drugstatin intoleranceHuman
researchProduct

Acute Postcataract Surgery Endophthalmitis Due to Streptococcus Species Differs From Endophthalmitis Due to Staphylococcus Species at Presentation

2009

Purpose: : To correlate the presenting clinical ophthalmic features with the bacterial identification in 100 patients with acute post catarcat endophthalmitis enrolled in the FRench Instutionnal ENdophthalmitis Study (FRIENDS).Methods: : Demographic data, past medical history and initial eye examination were recorded in a standardized form in 100 patients with acute endophthalmitis after cataract extraction (< 6 weeks) in a prospective multicenter study. Relationship between microbiological identification (using conventional cultures and panbacterial PCR) and clinical factors at baseline was studied using univariate (ANOVA).Results: : 100 patients were hospitalized for endophthalmitis treat…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyendophthalmitis[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organsmicrobial pathogenesis: clinical studiesbacterial disease
researchProduct

Understanding Addiction Using Animal Models

2019

Drug addiction is a neuropsychiatric disorder with grave personal consequences that has an extraordinary global economic impact. Despite decades of research, the options available to treat addiction are often ineffective because our rudimentary understanding of drug-induced pathology in brain circuits and synaptic physiology inhibits the rational design of successful therapies. This understanding will arise first from animal models of addiction where experimentation at the level of circuits and molecular biology is possible. We will review the most common preclinical models of addictive behavior and discuss the advantages and disadvantages of each. This includes non-contingent models in whi…

addiction modelsrelapse activityCognitive Neurosciencemedia_common.quotation_subjectVulnerabilityCravingReviewImpulsivitylcsh:RC321-57103 medical and health sciencesBehavioral Neuroscience0302 clinical medicinemedicinepreclinical studieslcsh:Neurosciences. Biological psychiatry. Neuropsychiatry030304 developmental biologymedia_commonFace validity0303 health sciencesAddictionmedicine.diseaseDSM-VSocial relation3. Good healthSubstance abuseNeuropsychology and Physiological Psychologydrug seeking behaviormedicine.symptomAddictive behaviorPsychology030217 neurology & neurosurgeryClinical psychologyFrontiers in Behavioral Neuroscience
researchProduct